Literature DB >> 18034767

Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women.

P L Meroni1, F Peyvandi, L Foco, L Bernardinelli, R Fetiveau, P M Mannucci, A Tincani.   

Abstract

BACKGROUND: Contrasting data have been reported on the association between the presence of anti-phospholipid antibodies (aPL) and arterial thrombotic events, particularly those in coronary arteries. This discrepancy is perhaps related to the confounding effect of traditional risk factors. Among them, coronary atherosclerosis appears to be the most important in studies conducted in middle-aged and elderly patients.
OBJECTIVE: To minimize such confounding effects, a multicenter case-control study on the association between aPL and myocardial infarction (MI) was carried out in a rare cohort of young premenopausal women.
METHODS: We evaluated 172 cases hospitalized for a first MI before the age of 45 years and 172 controls individually matched with cases for age, sex and geographical origin. Clinical and laboratory data were collected and levels of anti-cardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI) and anti-nuclear antibodies (ANA) were measured.
RESULTS: A significant association between MI and IgG/IgM anti-beta2GPI antibodies was observed; the results were confirmed after adjusting for smoking and hypertension (anti-beta2GPI IgG OR = 2.47, 95% CI 1.81-3.38; anti-beta2GPI IgM 4th quartile OR 3.68, 95% CI 1.69-8.02). The association between anti-beta2GPI antibodies and MI was detected in both subgroups with and without coronary artery stenosis. Whereas the association of aCL IgG with MI was modest, ANA showed no significant association with MI. No aPL were found in unselected patients (mainly males) who recently developed acute MI.
CONCLUSIONS: Anti-beta2GPI antibodies are a significant risk factor for MI in young premenopausal women independently of other risk factors, including the degree of coronary artery stenosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034767     DOI: 10.1111/j.1538-7836.2007.02763.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

1.  Hughes syndrome (the antiphospholipid syndrome): a disease of our time.

Authors:  Graham R V Hughes
Journal:  Inflammopharmacology       Date:  2010-12-05       Impact factor: 4.473

Review 2.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 3.  Is preclinical autoimmunity benign?: The case of cardiovascular disease.

Authors:  Darcy S Majka; Rowland W Chang
Journal:  Rheum Dis Clin North Am       Date:  2014-09-17       Impact factor: 2.670

4.  Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world.

Authors:  Xiaoli Deng; Xiangyuan Liu
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

Review 5.  New insights into the biology and pathobiology of beta2-glycoprotein I.

Authors:  Bill Giannakopoulos; Peyman Mirarabshahi; Steven A Krilis
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 6.  Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.

Authors:  Roberta Gualtierotti; Martina Biggioggero; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

7.  Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.

Authors:  Francesco Boin; Stefano Franchini; Elizabeth Colantuoni; Antony Rosen; Fredrick M Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2009-08

Review 8.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

9.  Prevalence of thrombophilic disorders in takotsubo patients: the (ThROmbophylia in TAkotsubo cardiomyopathy) TROTA study.

Authors:  Emanuele Cecchi; Guido Parodi; Serena Fatucchi; Paola Angelotti; Cristina Giglioli; Anna Maria Gori; Brunella Bandinelli; Benedetta Bellandi; Elena Sticchi; Ilaria Romagnuolo; Lucia Mannini; David Antoniucci; Rosanna Abbate
Journal:  Clin Res Cardiol       Date:  2016-03-22       Impact factor: 5.460

Review 10.  Management of cardiovascular disease risk in chronic inflammatory disorders.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.